1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. New Jersey >
  6. Curia Acquires Whitehouse Laboratories

M&A Deal Summary

Curia Acquires Whitehouse Laboratories

On December 15, 2015, Curia acquired life science company Whitehouse Laboratories for 54M USD

Acquisition Highlights
  • This is Curia’s 5th transaction in the Life Science sector.
  • This is Curia’s 5th largest (disclosed) transaction.
  • This is Curia’s 4th transaction in the United States.
  • This is Curia’s 1st transaction in New Jersey.

M&A Deal Summary
Date 2015-12-15
Target Whitehouse Laboratories
Sector Life Science
Buyer(s) Curia
Deal Type Add-on Acquisition
Deal Value 54M USD

Target

Whitehouse Laboratories

Lebanon, New Jersey, United States
Whitehouse Laboratories is a comprehensive analytical testing laboratory that offers USP-NF, EP, FCC and JP Monograph testing.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Curia

Albany, New York, United States
Category Company
Founded 1991
Sector Life Science
Employees2,220
Revenue 402M USD (2015)
DESCRIPTION

Curia is a contract development and manufacturing organization (CDMO) providing services from drug discovery through development and manufacturing for small molecules, generic APIs, and biologics. The company draws on many years of experience and operates globally with integrated facilities in North America, Europe, and Asia. Curia was founded in 1991 and is headquartered in Albany, New York.

DEAL STATS #
Overall 7 of 11
Sector: Life Science M&A 5 of 9
Type: Add-on Acquisition M&A Deals 6 of 8
State: New Jersey M&A 1 of 2
Country: United States M&A 4 of 7
Year: 2015 M&A 3 of 3
Size (of disclosed) 5 of 7
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-07-16 Gadea Grupo Farmacéutico SL

Valladolid, Spain

Gadea Grupo Farmacéutico SL (Gadea Pharmaceutical Group) is a technically complex active pharmaceutical ingredients (APIs) and finished drug product.

Buy $174M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-05-05 Archimica

Lodi, Italy

Archimica offers small- to large-scale commercial manufacturing as well as analytical support for the global biopharmaceutical market. The company is specialized in custom synthesis and the manufacture of active pharmaceutical ingredients (“APIs”). Archimica was founded in 1946 and is based in Lodi, Italy.

Buy $358M
Mergr

Solution for

Product

Company

Legal